NCT05550207Phase 3Completed

Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)

Study sponsor: Axsome Therapeutics, Inc. · AXSM

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-11-27Actual

Enrollment · participants100Actual

Source updated2025-12-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-12-02 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2024-10-16

+ Updated value

2024-11-27

Check registry source

Study details

Conditions studied

Migraine

Treatments or interventions studied

AXS-07 (meloxicam-rizatriptan)Drug

Primary outcomes · main study measures

Read the study measures

measure: Percentage of subjects with headache pain relief; description: Absence of headache pain and without the use of rescue medication.; timeFrame: Hour 2 following dose administration; measure: Percentage of subjects with absence of the Most Bothersome Symptom; description: Absence of the most bothersome symptom, defined at the onset of migraine.; timeFrame: Hour 2 following dose administration

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history